These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23177289)

  • 41. Treatment of chronic hepatitis C.
    Bihl F; Negro F
    Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
    Lee SS; Kilvert L; Liu H; Trepanier J
    Dig Liver Dis; 2016 Mar; 48(3):344. PubMed ID: 26459137
    [No Abstract]   [Full Text] [Related]  

  • 43. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
    Yoshida K; Hai H; Tamori A; Teranishi Y; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?
    Serfaty L
    Liver Int; 2014 Feb; 34 Suppl 1():11-2. PubMed ID: 24373072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
    Smith JA; Kalimullah FA; Erickson CP; Peng LS
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.
    Gallay PA
    Immunol Res; 2012 Jun; 52(3):200-10. PubMed ID: 22169996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Faldaprevir for the treatment of hepatitis C.
    Kanda T; Yokosuka O; Omata M
    Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HCV therapy in HIV-infected patients.
    Sulkowski MS
    Liver Int; 2013 Feb; 33 Suppl 1():63-7. PubMed ID: 23286848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New treatments for chronic hepatitis C virus infection.
    Corouge M; Pol S
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
    Fontana RJ; Hughes EA; Appelman H; Hindes R; Dimitrova D; Bifano M
    Liver Transpl; 2012 Sep; 18(9):1053-9. PubMed ID: 22706796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
    Diago M; Hassanein T; Rodés J; Ackrill AM; Sedarati F
    Ann Intern Med; 2004 Jan; 140(1):72-3. PubMed ID: 14706990
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.
    Inoue K; Umehara T; Ruegg UT; Yasui F; Watanabe T; Yasuda H; Dumont JM; Scalfaro P; Yoshiba M; Kohara M
    Hepatology; 2007 Apr; 45(4):921-8. PubMed ID: 17393519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal dosage of ribavirin.
    Mangia A; Andriulli A
    Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
    [No Abstract]   [Full Text] [Related]  

  • 59. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 60. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.
    Thompson A; Patel K; Tillman H; McHutchison JG
    J Hepatol; 2009 Jan; 50(1):184-94. PubMed ID: 19022518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.